Propranolol therapy for pediatric hemangioma and lymphangioma

Propranolol therapy for pediatric hemangioma and lymphangioma - Propranolol therapy for pediatric hemangioma and lymphangioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005990

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric hemangioma and lymphangioma

Interventions

propranolol therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemangioma and lymphangioma. informed consent.

Exclusion criteria

Exclusion criteria: Heart disease. hypotension. Patient who has drug allergy, and patient with the past of serious side effect by the propranolol drug. Patient who was considered ineligible by the investigators.

Design outcomes

Primary

Measure	Time frame
objective tumor response	—

Countries

Japan

Contacts

Public ContactTaichi Fukuzawa

Tohoku University Hospital Department of Pediatric Surgery

fukuzawa@ped-surg.med.tohoku.ac.jp022-717-7237

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026